Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone-resistant Prostate Cancer”

187 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 187 results

Testing effectiveness (Phase 2)Ended earlyNCT01093183
What this trial is testing

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer
University of Nebraska 25
Testing effectiveness (Phase 2)UnknownNCT02935205
What this trial is testing

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Metastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer
Mamta Parikh 38
Testing effectiveness (Phase 2)Study completedNCT01487720
What this trial is testing

GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Asan Medical Center 33
Testing effectiveness (Phase 2)Study completedNCT01075308
What this trial is testing

SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
NCIC Clinical Trials Group 32
Not applicableLooking for participantsNCT07691697
What this trial is testing

PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer

Who this might be right for
Oligoprogressive Prostate CancerMetastatic Prostate Cancer
Affidea Nu-med Center of Oncological DIagnostics and Therapy 1,000
Early research (Phase 1)Study completedNCT01144897
What this trial is testing

PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy

Who this might be right for
Castrate Resistant Prostate CancerProstate Cancer
Daniel Vaena 5
Early research (Phase 1)Looking for participantsNCT05997615
What this trial is testing

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Who this might be right for
Hormone-refractory Prostate Cancer
Astellas Pharma Global Development, Inc. 437
Testing effectiveness (Phase 2)Active Not RecruitingNCT02807805
What this trial is testing

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Who this might be right for
Metastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer
Mamta Parikh 37
Early research (Phase 1)Active Not RecruitingNCT06229366
What this trial is testing

[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancerOligometastatic Prostate Carcinoma+1 more
Eli Lilly and Company 142
Testing effectiveness (Phase 2)UnknownNCT03085966
What this trial is testing

Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Shanghai AbelZeta Ltd. 30
Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Not applicableLooking for participantsNCT06633380
What this trial is testing

Alternative Physical Activity Strategies for Breast Cancer Survivors

Who this might be right for
Breast CancerInsulin ResistanceCardiometabolic Risk Factors
University of Toronto 24
Early research (Phase 1)Ended earlyNCT01174199
What this trial is testing

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate CancerAdenocarcinoma of the ProstateHormone-resistant Prostate Cancer+2 more
Roswell Park Cancer Institute 13
Testing effectiveness (Phase 2)Study completedNCT02499835
What this trial is testing

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Soft Tissues+4 more
University of Wisconsin, Madison 66
Large-scale testing (Phase 3)Active Not RecruitingNCT06551324
What this trial is testing

Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer 600
Testing effectiveness (Phase 2)Study completedNCT02601014
What this trial is testing

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

Who this might be right for
Prostate CancerRecurrent Prostate CarcinomaStage IV Prostate Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 32
Testing effectiveness (Phase 2)Study completedNCT00436956
What this trial is testing

AZD2171 to Treat Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 59
Testing effectiveness (Phase 2)Ended earlyNCT01267266
What this trial is testing

Saracatinib in Treating Patients With Prostate Cancer

Who this might be right for
Hormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
National Cancer Institute (NCI) 31
Not applicableLooking for participantsNCT07290270
What this trial is testing

Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

Who this might be right for
Metastatic Prostate Cancer
Novartis Pharmaceuticals 170
Testing effectiveness (Phase 2)Study completedNCT00636740
What this trial is testing

Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

Who this might be right for
Hormone-Refractory Prostate Cancer
Merrion Pharmaceuticals, LLC 30
Next Page